Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
insulin aspart + liraglutide
- Development stage
- Unknown
- Lead developer
- Novo Nordisk
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous
01
Overview
This describes a hypothetical fixed-dose combination of insulin aspart (a rapid-acting insulin analog) and liraglutide (a GLP-1 receptor agonist). While both components exist as individual medications and are used in diabetes treatment, the search results do not indicate that this specific combination is an approved fixed-dose combination product. Insulin aspart works by lowering blood glucose levels. Liraglutide is a GLP-1 receptor agonist, similar to a naturally occurring hormone, which helps control blood sugar, insulin levels, and digestion.
02
Targets
INSR (Insulin receptor)GLP1R (GLP-1R)
Beyond the preview
Go deeper on insulin aspart + liraglutide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on insulin aspart + liraglutide.